THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY

Introduction: The prognosis of TP53 biallelic-mutated AML/MDS is severely poor. Azacitidine, venetoclax combination therapy (Aza/Ven) was shown to be effective and tolerable for AML patients who cannot receive standard chemotherapy and the efficacy even for adverse risk AML is expected. Methods: We...

Full description

Bibliographic Details
Main Authors: T. Ueda, K. Fukushima, Y. Nannya, A. Hino, M. Hamada, Y. Mizutani, E. Mizuta, C. Hasegawa, Y. Yamaguchi, R. Kurashige, R. Nakai, S. Kusakabe, M. Ichii, J. Fujita, N. Hosen
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Leukemia Research Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2213048924000384

Internet

http://www.sciencedirect.com/science/article/pii/S2213048924000384

Similar Items